â??A Study to Evaluate the Efficacy of Shirobasti(Pulling of medicated oil) and Nasya(medicinal nasal drops) With and Without Medicine (Levodopa) in the Management of Kampavata (Parkinsonâ??s Disease).

â??An Open Clinical Study to Evaluate the Efficacy of Shirobasti and Nasya With and Without Levodopa in the Management of Kampavata w.s.r. to Parkinsonâ??s Disease (PD).

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2018/08/015533

Enrollment

Registered

2018-08-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: G20-G26- Extrapyramidal and movement disorders Health Condition 2: G32- Other degenerative disorders of nervous system in diseases classified elsewhere Health Condition 3: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhere Health Condition 4: G328- Other specified degenerative disorders of nervous system in diseases classified elsewhere

Interventions

Intervention1: Group A: In this group 15 patient those receiving Levodopa in fixed dose will be undergone Shirobasti and Nasya with Ksheerbala Taila for 14 days. 1. Shirobasti - The oil is poured on t

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients between 40-70 years of age. 2. Patients with clinical signs and symptoms of Kampavata/ PD. 3. Patients of either sex irrespective of their occupation, religion and socio-economic status. 4. Patients of kampavata/PD who are on a fixed dose of levodopa and fit for Shirobasti and Nasya. 5. Patients of kampavata/PD who are not on levodopa and fit for Shirobasti and Nasya. 6. Patients willing to participate for interventional study.

Exclusion criteria

Exclusion criteria: 1. Patients with severe systemic disorders as Uncontrolled Hypertension, Cardiac Problem, Diabetes Mellitus, Tuberculosis, Leprosy, Paralysis, malignant disease etc. 2. Patients unfit for Shirobasti and Nasya.

Design outcomes

Primary

Measure	Time frame
Assessment of changes in specific signs and symptoms of Kampavata/PD.Timepoint: 45 days	—

Secondary

Measure	Time frame
Any adverse effect in the values of hematological test and in clinical signs and symptoms.Timepoint: 45 days	—

Countries

India

Contacts

Public ContactDr Jatinder Verma

National Institute of Ayurveda

gmangal108@gmail.com8619849011

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026